David M. Peereboom
Oncology | Hematology Oncology
10201 Carnegie Avenue
Cleveland, OH 44106
Cleveland, OH 44106
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications
TIP26-314: Targeting Macrophage Migration Inhibitory Factor: A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 01, 2026
TIP26-314: Targeting Macrophage Migration Inhibitory Factor: A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Racial Disparities in Glioblastoma: Can We Untangle Biological From Nonbiological Forces?
Journal: JCO oncology practice
Published: March 12, 2026
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.
Journal: Neuro-oncology
Published: November 26, 2025
Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.
Journal: Neuro-oncology
Published: November 26, 2025
Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab.
Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab.
Journal: Neuro-oncology advances
Published: October 24, 2025
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
Journal: Nature medicine
Published: August 29, 2025
Role of Immunotherapy and Targeted Agents to Treat Brain Metastases.
Journal: Cancer journal (Sudbury, Mass.)
Published: August 19, 2025
Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM.
Journal: Cancer immunology, immunotherapy : CII
Published: August 15, 2025
Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma.
Journal: Neuro-oncology
Published: August 04, 2025
Last Updated: 09/26/2026